Spero Therapeutics, Inc. (SPRO)

NASDAQ: SPRO · IEX Real-Time Price · USD
1.690
+0.040 (2.42%)
Mar 1, 2024, 4:00 PM EST - Market closed
2.42%
Market Cap 89.57M
Revenue (ttm) 77.70M
Net Income (ttm) -1.61M
Shares Out 53.00M
EPS (ttm) 0.39
PE Ratio 4.33
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 164,693
Open 1.640
Previous Close 1.650
Day's Range 1.625 - 1.728
52-Week Range 0.990 - 1.995
Beta 0.55
Analysts Strong Buy
Price Target 7.00 (+314.2%)
Earnings Date Mar 28, 2024

About SPRO

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and S... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 2, 2017
Employees 35
Stock Exchange NASDAQ
Ticker Symbol SPRO
Full Company Profile

Financial Performance

In 2022, SPRO's revenue was $53.51 million, an increase of 193.10% compared to the previous year's $18.26 million. Losses were -$46.42 million, -48.29% less than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for SPRO stock is "Strong Buy" and the 12-month stock price forecast is $7.0.

Price Target
$7.0
(314.20% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatme...

4 days ago - GlobeNewsWire

Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference

CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...

6 days ago - GlobeNewsWire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in...

4 weeks ago - GlobeNewsWire

Spero Therapeutics Provides Corporate Update and 2024 Outlook

In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients

2 months ago - GlobeNewsWire

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

$95 million in development milestones payable over two years, as part of GSK license agreement $95 million in development milestones payable over two years, as part of GSK license agreement

2 months ago - GlobeNewsWire

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializ...

4 months ago - GlobeNewsWire

SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Spero Therapeutics, Inc. (NASDAQ: SPRO) on b...

4 months ago - Business Wire

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

Ms. Rajavelu brings over two decades of experience in the life sciences sector focused on strategic growth, financing, M&A, and investor relations. Ms. Rajavelu brings over two decades of experience i...

4 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Spero Therapeutics, Inc. (NASDAQ: SPRO) for Potential Breaches of Fiduciary Duty By Its Board of Directors

NEW YORK , Oct. 11, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim...

5 months ago - PRNewsWire

Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference

CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and com...

5 months ago - GlobeNewsWire

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and com...

6 months ago - GlobeNewsWire

Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializ...

7 months ago - GlobeNewsWire

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023

7 months ago - GlobeNewsWire

Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

Sath Shukla, current Spero Chief Financial Officer, will bring more than 20 years of strategic and financial leadership to the role of CEO, to be effective August 1, 2023

9 months ago - GlobeNewsWire

Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update

Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD) on track for top line data readout in 1H 2024

10 months ago - GlobeNewsWire

Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializi...

10 months ago - GlobeNewsWire

Spero Therapeutics to Present at Upcoming Investor Conference

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and com...

11 months ago - GlobeNewsWire

Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commerciali...

11 months ago - GlobeNewsWire

Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update

Initiated proof-of-concept Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); top line data expected in 1H 2024

1 year ago - GlobeNewsWire

Spero Therapeutics Reschedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call to March 30, 2023

CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commerciali...

1 year ago - GlobeNewsWire

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023

CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commerciali...

1 year ago - GlobeNewsWire

Spero Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and comm...

1 year ago - GlobeNewsWire

Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and comm...

1 year ago - GlobeNewsWire

Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update

Entered into and closed exclusive license agreement with GSK for tebipenem HBr, pursuant to which Spero receives $66 million upfront, and a $9 million direct equity investment in Spero shares of commo...

1 year ago - GlobeNewsWire

Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr

Pursuant to the agreement, Spero will be receiving a $66 million upfront payment, received a $9 million direct equity investment in shares of Spero common stock, and is eligible for potential future m...

1 year ago - GlobeNewsWire